Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus ; day:25 ; month:4 ; year:2016 ; pages:1-12
Diabetes therapy ; (25.4.2016), 1-12
- Urheber
-
Katsuno, Tomoyuki
- Beteiligte Personen und Organisationen
-
Ikeda, Hiroki
Namba, Mitsuyoshi
SpringerLink (Online service)
- DOI
-
10.1007/s13300-016-0170-2
- URN
-
urn:nbn:de:1111-201604262152
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Katsuno, Tomoyuki
- Ikeda, Hiroki
- Namba, Mitsuyoshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates inflammation and autophagy in mice hindlimb ischemia–reperfusion injury
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial
Effekte des DPP-IV Inhibitors Sitagliptin auf die Ausdehnung und Stabilität arteriosklerotischer Läsionen in Apolipoprotein E defizienten Mäusen
Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
"DPP' 94"
Synthesis of (S)-Sitagliptin
Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates inflammation and autophagy in mice hindlimb ischemia–reperfusion injury
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial
Effekte des DPP-IV Inhibitors Sitagliptin auf die Ausdehnung und Stabilität arteriosklerotischer Läsionen in Apolipoprotein E defizienten Mäusen
Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
"DPP' 94"
Synthesis of (S)-Sitagliptin
Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates inflammation and autophagy in mice hindlimb ischemia–reperfusion injury
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial
Effekte des DPP-IV Inhibitors Sitagliptin auf die Ausdehnung und Stabilität arteriosklerotischer Läsionen in Apolipoprotein E defizienten Mäusen
Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
"DPP' 94"